Gossamer Bio, Inc. (NASDAQ: GOSS)

This lawsuit is for anyone who acquired securities in Gossamer Bio, Inc. (NASDAQ: GOSS) from June 16, 2025 through February 20, 2026.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by telling investors that the Company was likely to receive FDA approval of seralutinib for the treatment of pulmonary arterial hypertension based on the Company’s Phase 3 PROSERA study of the drug despite knowing that the study could not support approval because the study group was not very sick, meaning there could be no meaningful difference in the results of the people receiving the drug and the placebo.

On February 23, 2026, Gossamer disclosed that results for its Phase 3 PROSERA study of seralutinib for the treatment of pulmonary arterial hypertension had failed to meet the primary endpoint, citing patients at Latin American sites performing particularly well on placebo due to enrollment of a heavily-treated lower-risk population. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Gossamer Bio, Inc. (NASDAQ: GOSS) from June 16, 2025 through February 20, 2026 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.